Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Cash & Equivalents (2018 - 2025)

Exagen's Cash & Equivalents history spans 8 years, with the latest figure at $32.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 46.12% year-over-year to $32.2 million; the TTM value through Dec 2025 reached $32.2 million, up 46.12%, while the annual FY2025 figure was $32.2 million, 46.12% up from the prior year.
  • Cash & Equivalents reached $32.2 million in Q4 2025 per XGN's latest filing, down from $35.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $118.0 million in Q1 2021 to a low of $11.2 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $54.4 million, with a median of $36.1 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 76.77% in 2021, then tumbled 58.92% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $99.4 million in 2021, then tumbled by 37.26% to $62.4 million in 2022, then crashed by 41.51% to $36.5 million in 2023, then tumbled by 39.62% to $22.0 million in 2024, then skyrocketed by 46.12% to $32.2 million in 2025.
  • Per Business Quant, the three most recent readings for XGN's Cash & Equivalents are $32.2 million (Q4 2025), $35.7 million (Q3 2025), and $30.0 million (Q2 2025).